TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Epodure Therapy of Anemia in End Stage Renal Disease on Dialysis With Epodure Skin Implant

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:1.~1. Adult male or female subjects between 18 to 75 years of age at the time of screening visit.~2. Subject diagnosed with Anemia due to Chronic Renal Failure CKD stage 5 on dialysis treatment for at least 3 months. Hb \< 12g/dL on 2 consecutive measures~3. Kt/V \>1~4. INR not higher than 1.2~5. Subjects who are clinically stable.~6. Serum albumin \> 3.5~7. Subjects with adequate iron stores (transferrin saturation \> 20.0% and/or ferritin \> 100 ng/ml).~8. Signed written informed consent to participate in the study.~Exclusion Criteria:~1. Uncontrolled hypertension (defined as diastolic blood pressure \> 110 mmHg or systolic blood pressure \> 180 mmHg during screening).~2. Subjects who receive oral anti-coagulation treatment (warfarin)~3. Subjects who receive Acetyl Salicylic Acid \[(ASA), aspirin\] above 325 mg/day or patients who receive ASA treatment between 100mg/d and 325 mg/d who cannot discontinue it for 1 week prior to each EPODURE procedure~4. Patients currently receiving injections of long-acting ESA's (Aranesp, Mircera, etc.)~5. Congestive heart failure (New York Heart Association functional class III or IV).~6. Grand mal seizures within 2 years of the screening visit.~7. Clinical evidence of severe hyperparathyroidism as defined by PTH levels of \> 10 times the upper normal limits.~8. Major surgery within 12 weeks of the screening visit.~9. Systemic hematologic diseases (e.g., sickle cell anemia, myelodysplastic syndromes, hematologic malignancy, myeloma, hemolytic anemia).~10. Current systemic infection, active inflammatory disease, or malignancy under treatment.~11. Subjects known to have tested positive at any time in the past for antibodies to erythropoietic proteins.~12. Subject has history of malignancy within the past 2 years prior to the screening visit, with the exception of basal cell carcinoma.~13. Subjects with other concurrent severe and/or uncontrolled medical condition which could compromise participation in the study (i.e. active infection, uncontrolled diabetes, uncontrolled hypertension, congestive cardiac failure, unstable angina, ventricular arrhythmias, active ischemic heart disease, myocardial infarction within six months, uncompensated cirrhosis, active upper GI tract ulceration).~14. Subject is currently enrolled in, or has not yet completed a period of at least 30 days since ending other investigational device or drug trial(s).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- EPODURE Low dose (Type: EXPERIMENTAL): EPODURE pump secreting hEPO 18-25 IU/kg/day

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Effect of ZT-01 on Glucagon During Hypoglycemia in Type 1 Diabetes Mellitus

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion Criteria:~* Type 1 diabetes for at least 5 years and receiving insulin as the only T1D therapy~* HbA1c ≥6.0 and ≤9.0 %~* BMI ≥18 to ≤27 kg/m\^2~* Normal thyroid function~Exclusion Criteria:~* Impaired hypoglycemia awareness~* Severe hypoglycemia or diabetic ketoacidosis (DKA) within 3 months~* Abnormal blood pressure or ECG, clinically significant cardiovascular, cerebrovascular or peripheral vascular disease~* History of pheochromocytoma, insulinoma, glucagonoma, acromegaly, Cushing's disease, glycogen storage disease or adrenal insufficiency; ongoing or previous treatment with octreotide, lanreotide or pasireotide~* Current use of systemic corticosteroids or beta-blockers

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Treatment order: placebo, low dose, high dose (Type: EXPERIMENTAL): Subjects will receive a single administration of each treatment in this order during three consecutive clamps
- Treatment order: placebo, high dose, low dose (Type: EXPERIMENTAL): Subjects will receive a single administration of each treatment in this order during three consecutive clamps
- Treatment order: low dose, placebo, high dose (Type: EXPERIMENTAL): Subjects will receive a single administration of each treatment in this order during three consecutive clamps
- Treatment order: low dose, high dose, placebo (Type: EXPERIMENTAL): Subjects will receive a single administration of each treatment in this order during three consecutive clamps
- Treatment order: high dose, placebo, low dose (Type: EXPERIMENTAL): Subjects will receive a single administration of each treatment in this order during three consecutive clamps
- Treatment order: high dose, low dose, placebo (Type: EXPERIMENTAL): Subjects will receive a single administration of each treatment in this order during three consecutive clamps

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Assessment of the Safety and Efficacy of Weighted Wearable Blankets in Healthy Infants During Sleep

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Ability of parent, caregiver or legal guardian/representative to understand a written informed consent document and choose to participate in the study~* 0-12 months of age~* Weight greater than or equal to 8 pounds~* Gestational age 37 weeks or greater~* Health status: healthy infant without underlying cardiac, neurological, or pulmonary disorders~* Infant is naive to a weighted wearable blanket~Exclusion Criteria:~* Health status: medical diagnosis associated with underlying cardiac, neurological, or pulmonary disorder~* Weight \< 8 pounds~* Gestational age \< 37 weeks~* Gestational use of marijuana, alcohol, or illicit drugs~* Home environment: use of cigarettes, vaping, e-cigarettes, or marijuana~* Infant is not naive to a weighted wearable blanket

- Gender: ALL
- Minimum Age: 1 Day
- Maximum Age: 12 Months
- Healthy Volunteers: t

Study Arms:
- Pilot (Type: EXPERIMENTAL): Weighted wearable blanket, provided by Dreamland Baby Co.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: safety issues
Please assess the completion status of the following clinical trial:

Trial Title: High-Dose Quinapril Versus Low-Dose Quinapril Plus Amlodipine in the Treatment of High-Risk Hypertensive Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patients with a documented history of hypertension defined as: SBP \> or = 140 mmHg or DBP \> or = 90 mmHg if hypertension untreated or patients currently treated for hypertension.~* Documented CAD or diabetes or impaired glucose tolerance~* Sinus rhythm~Principal Exclusion Criteria:~* Previous intolerance or allergic reaction to an ACE inhibitor, an ARB or dihydropyridine calcium channel blocker~* History of angioedema or cough related to previous ACE inhibitor use.~* Systolic blood pressure \> 180 mmHg or diastolic blood pressure \> 110 mmHg in untreated patients~* Systolic blood pressure \> 160 mmHg or diastolic blood pressure \> 100 mmHg in patients currently treated by an ACE inhibitor or an ARB~* Creatinine clearance \< 30 ml/min~* Significant liver dysfunction~* Current serum potassium \> or = 5 mmol/L or a history of marked ACE inhibitor or ARB induced hyperkalemia resulting in either a serum potassium \> or = 5.5 mmol/L or a life-threatening adverse event.~* History of HF or known LVEF \< or = 45%~* Bilateral renal artery stenosis (or unilateral if only one kidney)~* Unstable angina, myocardial infarction or coronary revascularization within the last 3 months.~* Connective tissue disease or chronic inflammatory condition~* Active malignancy~* Active infection in the last 2 weeks~* Inability or any contraindication to perform an exercise test.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: A Trial Examining the Efficacy of Escitalopram Oxalate Upon Depressive Symptoms and Fatigue in HIV Seropositive Women

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of major depression based on DSM-IV criteria;~* age 18-70 years;~* Greater than 15 on MADRS for severity of depression;~* HIV seropositive;~* no new antiviral medications over the past 2 months;~* involved in active treatment for HIV disease,~* negative serum pregnancy test~* Those subjects who are actively being treated for depression but show no improvement as defined by self-reported failure to improve with current treatment or residual depression as demonstrated by a MADRS of 15 or greater will be asked to participate in the study as well.~Exclusion Criteria:~* The presence of an active and significant psychiatric disease other than Major Depressive Disorder as diagnosed on MINI in the last 3 months;~* meeting DSM-IV criteria for an Axis I disorder within the last three months, or meeting criteria for substance abuse within the last 12 months;~* current pregnancy or lactation if breast feeding;~* history of hypersensitivity, intolerance, or contraindication to LEX;~* baseline creatinine of 2.5 or greater;~* patients taking anticoagulants;~* history of diagnosed gastric or duodenal ulcer;~* history within past year of bleeding or clotting diathesis;~* lifetime history of myocardial infarction or cerebrovascular accident;~* history of surgery within the past 3 months;~* inability to follow study procedures or complete the study;~* the use of any antidepressant medications within 5 half-lives of randomization;~* women of child-bearing potential who will not agree to use approved means of birth control during the trial;~* other reason that the primary investigator believes that the subject will be unable to complete trial or has medical/psychiatric contraindications to the trial.~* Individuals who are currently being treated for depression and show significant improvements in their depression such that discontinuing their current antidepressant therapy would likely have negative clinical consequences will be excluded from participating in this study.~* Individuals who are or become suicidal will be excluded from this study.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Sugar Pill (Type: PLACEBO_COMPARATOR): Placebo
- Active Drug (Type: ACTIVE_COMPARATOR): Escitalopram tablet, 10mg, daily, 9 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Ureteral Stent Length and Patient Symptoms

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: None
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria: Male or female over 18 years of age, will be receiving electro-shock wave therapy for kidney stones -~Exclusion Criteria:Under 18 years of age, inability to give informed consent~-

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Linagliptin in Schizophrenia Patients

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* 18 years of age and above~* Diagnosis of schizophrenia.~* Clinically stable antipsychotic regimen for the last 3 months~* A total score of 80 or greater at baseline on the Positive and Negative Syndrome Scale~* Competent and willing to provide written, informed consent~Exclusion Criteria:~* History of substance dependence within the past 2 months~* Existing relevant physical health problems: such as uncontrolled cardiovascular disease and impaired liver/ renal function~* History of diabetes~* History of hepatic or biliary diseases / biliary obstruction~* A serious suicide/homicide risk in the opinion of the investigator~* Known allergy to linagliptin

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Linagliptin (Type: EXPERIMENTAL): Linagliptin daily

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Radiation Therapy on Pelvic Floor Disorders in Women

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: RETROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Living, female patients.~* Age 18 or older with a diagnosis of colorectal cancer (current or past, regardless of Stage)-confirmed by pathology report - made between the years of 2015 and 2018.~* History of treatment for colorectal cancer in the Wake Forest Baptist Health System.~* Sexual partners of the above participants (subjects can participate even if they are not sexually active or if no sexual partner is available).~* English speaking.~Exclusion Criteria:~* No internet access.~* Non-English speakers (validated instruments are only available in English).

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Surgery Only Group (Type: None): Participants will complete a questionnaires regarding demographics and medical history on a secured REDCap link.
- Surgery and Radiation Therapy Group (Type: None): Participants will complete a questionnaires regarding demographics and medical history on a secured REDCap link.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: regulatory/approval
Please assess the completion status of the following clinical trial:

Trial Title: Sodium Pertechnetate (99Tc) Injection Generator: 99mTc From Neutron-activation 99Mo v 99mTc From Fission 99Mo

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Oncology out-patients in whom an acceptable quality standard-of-care Technetium (99mTc) Medronate bone scan has been ordered or obtained within the last 28 days.~* If female of child-bearing potential is outside of the window of 10 days since the last menstrual period, a negative serum pregnancy test is required.~* Age greater than or equal to 18 years.~Exclusion Criteria:~* Oncology out-patients in whom an acceptable quality standard-of-care Technetium (99mTc) Medronate bone scan has been ordered or obtained within the last 28 days.~* If female of child-bearing potential is outside of the window of 10 days since the last menstrual period, a negative serum pregnancy test is required.~* Age greater than or equal to 18 years.~* Identified interval events which have occurred after the standard of care bone scan but prior to the administration of non-fission sourced Technetium (99mTc) Medronate which could influence or change bone scan uptake (e.g. skeletal trauma, orthopedic surgery, bone infection, or interval therapy (i.e. radiation therapy, non-maintenance chemotherapy). -

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 99mTc MDP Injection:neutron-bombardment (Type: EXPERIMENTAL): Oncologic indication for which a bone scan would normally be indicated. Participant having recently had a bone scan using Technetium (99mTc) Medronate Injection USP labeled with 99mTc derived from fission-sourced 99Mo. The images of the 99mTc MDP Injection-neutron-bombardment will be compared to the previous (on file) images from the 99mTc MDP Injection-fission

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Colony Stimulating Factor on Poor Endometrial Development During IVF

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patient's preparing for invitro fertilization and embryo transfer with endometrial growth of less than 7 mm, unresponsive to standard treatment~Exclusion Criteria:~* Sickle Cell disease~* Renal insufficiency~* Upper respiratory infection or Pneumonia~* Chronic Neutropenia~* Known Past or present malignancy

- Gender: FEMALE
- Minimum Age: 21 Years
- Maximum Age: 45 Years
- Healthy Volunteers: t

Study Arms:
- G-CSF (Type: EXPERIMENTAL): G-CSF 300 units administered by trans-cervical infusion one time on day of hCG trigger for Ovulation
- Saline (Type: PLACEBO_COMPARATOR): Saline administered by trans-cervical infusion one time on day of hCG trigger for ovulation

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Characterization of Brachial Arterial t-PA Release, Endothelial Function, Obesity and Inflammation

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion criteria:~1. Adults 18 years and greater~2. Healthy~Exclusion criteria:~1. PVC \< 30~2. Hypertensive subjects on ACE inhibitors~3. Pregnant or nursing mothers~4. Diabetic with HbA1C \> 7.5 or stigmata of end organ damage (neuropathy, retinopathy, nephropathy, cardiomyopathy)~5. Cholesterol \> 30 mg/dL above NCEP accepted level based on cardiac risk.~6. Triglycerides \> 200~7. Previously diagnosed obstructive coronary artery disease, myocardial infarction or left ventricular dysfunction (with or without a history of congestive heart failure)~8. Renal insufficiency (Creatinine ≥ 1.5 mg/dl)~9. History of cerebrovascular disease~10. Any chronic inflammatory disease (rheumatologic, inflammatory bowel disease, etc)~11. Uncontrolled Stage 2 Hypertension (160/100 mmHg), or end organ damage due to hypertension (left ventricular hypertrophy, atrial fibrillation, hematuria, renal insufficiency, prior cerebrovascular disease).~12. Angiotensin converting enzyme inhibitor use~13. Coagulopathy (INR ≥ 1.5, PTT ≥ 1.5 x control)~14. Other chronic medical illnesses at the discretion of the investigators

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Bradykinin (Type: EXPERIMENTAL): Patients will have flow mediated vasodilation and radial artery tonometry performed. They will then receive 0, 10, 20, 40 ng/100cc/min of intrabrachial bradykinin. Strain gauge plethysmography and blood sampling at each dose will be done to evaluate t-PA release. Blood will also be drawn for other biomarkers.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of the Benefit of Antiviral Treatment With Valganciclovir on Congenital CMV Infection-related Deafness on Hearing and Balance

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Children ≥ 6 months old and \< 12 years old~* Past history of proven congenital CMV infection~* Auditory threshold of between 40 and 90 dB in at least 1 ear.~Exclusion Criteria:~* Bilateral deafness \> 90 dB~* Contraindication to valganciclovir, particularly: Neutropenia with a known neutrophil count of \<500/mm3, Hb\<8g/dl or platelets\< 25,000/mm3 (FBC to be confirmed before randomisation)~* Past history of neutropenia on valganciclovir or allergy to the compound~* Renal impairment with creatinine clearance of \< 10 ml/min/1.72m2 (confirmation of renal function before randomisation) according to the Schwartz equation~* Patients on other antiviral treatment~* Gastrointestinal absorption problems~* Patients participating in a biomedical research project on a medicinal product or similar product

- Gender: ALL
- Minimum Age: 6 Months
- Maximum Age: 12 Years
- Healthy Volunteers: f

Study Arms:
- Valganciclovir (Type: EXPERIMENTAL): Oral valganciclovir (Rovalcyte 50 mg/ml, powder for oral suspension), at a dose of 16 mg/kg 2 times/day (max 900 mg/d) for 6 weeks.
- Control group (Type: NO_INTERVENTION): Control group with standard care who do not receive the investigational medicinal product

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues